Denosumab biosimilars enhance treatment access for postmenopausal osteoporosis, demonstrating equivalent efficacy and safety ...

Australia's biosimilar adoption significantly reduces biologic medicine costs, enhancing access while maintaining utilization ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...

Explore the safety and efficacy of switching to etanercept biosimilars, backed by clinical trials and real-world evidence for ...

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving ...

There are critical gaps in biosimilar adoption for pediatric patients, focusing on safety, regulatory challenges, and the ...

UK neurologists release new guidelines for JC virus testing in patients using the natalizumab biosimilar Tyruko, addressing safety and monitoring challenges. To address growing uncertainty over JC ...

FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market access and affordability. The FDA has issued draft guidance that ...

A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration (nAMD), enhancing patient access to treatment. A biosimilar to aflibercept ...